FDA drug safety committee
This article was originally published in The Tan Sheet
The first in a series of meetings held by the Drug Safety & Risk Management Advisory Committee will take place May 18 and 19 at the Holiday Inn in Silver Spring, Md., 8:30 am - 5 pm, according to an April 14 Federal Register notice. Panelists will consider the advantages and disadvantages of FDA's current risk assessment program and safety detection of marketed drugs, including "review and analysis" of spontaneous adverse events reports, drug use data, administrative data, epidemiologic and observational studies, clinical trials and active surveillance systems...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."